PTPN 2 phosphatase deletion in T cells promotes anti‐tumour immunity and CAR T‐cell efficacy in solid tumours

T-Cell–Specific PTPN2 Deficiency in NOD Mice Accelerates the Development of Type 1 Diabetes and Autoimmune Comorbidities

(2019) Florian Wiede et al.   DIABETES

Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer

(2019) James W. Opzoomer et al.   Frontiers in Immunology

Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity

(2018) A. J. Davenport et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Emerging strategies for combination checkpoint modulators in cancer immunotherapy

(2018) Aleksandra Popovic et al.   JOURNAL OF CLINICAL INVESTIGATION

Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies

(2018) Roberta Zappasodi et al.   CANCER CELL

Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC

(2018) Marcus Grohmann et al.   CELL

Tissue-resident memory CD8+ T cells promote melanoma–immune equilibrium in skin

(2018) Simone L. Park et al.   NATURE

PTPN2: a tumor suppressor you want deleted?

(2017) Florian Wiede et al.   IMMUNOLOGY AND CELL BIOLOGY

CAR T-cell therapy of solid tumors

(2017) Carmen S M Yong et al.   IMMUNOLOGY AND CELL BIOLOGY

PTPN2-deficiency exacerbates T follicular helper cell and B cell responses and promotes the development of autoimmunity

(2017) Florian Wiede et al.   JOURNAL OF AUTOIMMUNITY

Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy

(2017) Paul A. Beavis et al.   JOURNAL OF CLINICAL INVESTIGATION

PTPN2 regulates T cell lineage commitment and αβ versus γδ specification

(2017) Florian Wiede et al.   JOURNAL OF EXPERIMENTAL MEDICINE

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target

(2017) Robert T. Manguso et al.   NATURE

Targeted disruption of TC-PTP in the proliferative compartment augments STAT3 and AKT signaling and skin tumor development

(2017) Hyunseung Lee et al.   Scientific Reports

Genetic variants of PTPN2 are associated with lung cancer risk: a re-analysis of eight GWASs in the TRICL-ILCCO consortium

(2017) Yun Feng et al.   Scientific Reports

CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer

(2016) Holger Bronger et al.   BRITISH JOURNAL OF CANCER

Toxicity and management in CAR T-cell therapy

(2016) Challice L Bonifant et al.   Molecular Therapy-Oncolytics

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

(2015) S. Loi et al.   CLINICAL CANCER RESEARCH

Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer

(2015) C. N. Johnstone et al.   Disease Models & Mechanisms

CXCR3 Chemokine Receptor Enables Local CD8+ T Cell Migration for the Destruction of Virus-Infected Cells

(2015) Heather D. Hickman et al.   IMMUNITY

Protein Tyrosine Phosphatases in Hypothalamic Insulin and Leptin Signaling

(2015) Zhong-Yin Zhang et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Cross-presentation of cutaneous melanoma antigen by migratory XCR1+CD103−and XCR1+CD103+dendritic cells

(2015) Ben Wylie et al.   OncoImmunology

Trafficking of T Cells into Tumors

(2014) C. Y. Slaney et al.   CANCER RESEARCH

Hepatic Oxidative Stress Promotes Insulin-STAT-5 Signaling and Obesity by Inactivating Protein Tyrosine Phosphatase N2

(2014) Esteban N. Gurzov et al.   Cell Metabolism

Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins

(2014) S. Kim et al.   GENOME RESEARCH

PTPN2 restrains CD8+ T cell responses after antigen cross-presentation for the maintenance of peripheral tolerance in mice

(2014) Florian Wiede et al.   JOURNAL OF AUTOIMMUNITY

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

(2014) Antonella Sistigu et al.   NATURE MEDICINE

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

PTPN2 attenuates T-cell lymphopenia-induced proliferation

(2014) Florian Wiede et al.   Nature Communications

Active STAT5 Regulates T-bet and Eomesodermin Expression in CD8 T Cells and Imprints a T-bet-Dependent Tc1 Program with Repressed IL-6/TGF- 1 Signaling

(2013) M. Grange et al.   JOURNAL OF IMMUNOLOGY

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer

(2013) S. Loi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Sorting Through Subsets

(2012) Christopher A. Klebanoff et al.   JOURNAL OF IMMUNOTHERAPY

TCPTP Regulates SFK and STAT3 Signaling and Is Lost in Triple-Negative Breast Cancers

(2012) Benjamin J. Shields et al.   MOLECULAR AND CELLULAR BIOLOGY

Strain-Dependent Differences in Bone Development, Myeloid Hyperplasia, Morbidity and Mortality in Ptpn2-Deficient Mice

(2012) Florian Wiede et al.   PLoS One

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

(2011) R. J. Brentjens et al.   BLOOD

Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors

(2011) S. R. Mattarollo et al.   CANCER RESEARCH

Elevated Hypothalamic TCPTP in Obesity Contributes to Cellular Leptin Resistance

(2011) Kim Loh et al.   Cell Metabolism

T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice

(2011) Florian Wiede et al.   JOURNAL OF CLINICAL INVESTIGATION

Treatment of HER2-positive breast cancer: current status and future perspectives

(2011) Carlos L. Arteaga et al.   Nature Reviews Clinical Oncology

Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen

(2010) S Peinert et al.   GENE THERAPY

An autoimmune-associated variant in PTPN2 reveals an impairment of IL-2R signaling in CD4+ T cells

(2010) S A Long et al.   GENES AND IMMUNITY

Interleukin-2 and Inflammation Induce Distinct Transcriptional Programs that Promote the Differentiation of Effector Cytolytic T Cells

(2010) Matthew E. Pipkin et al.   IMMUNITY

Tumor masses support naive T cell infiltration, activation, and differentiation into effectors

(2010) Elizabeth D. Thompson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

T-bet and Eomesodermin Are Required for T Cell-Mediated Antitumor Immune Responses

(2010) Y. Zhu et al.   JOURNAL OF IMMUNOLOGY

Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

(2009) Carsten Denkert et al.   JOURNAL OF CLINICAL ONCOLOGY

Acquisition of a Potent and Selective TC-PTP Inhibitor via a Stepwise Fluorophore-Tagged Combinatorial Synthesis and Screening Strategy

(2009) Sheng Zhang et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice

(2008) J A Westwood et al.   GENE THERAPY